LMWH

Description Results NMA

Ardeparin 90 and 50 units/kg b.i.d (n=595)

vs.

UFH 10 000 units (n=309)

Blind

Sample size: 595/309

Primary endpoint:

FU duration:

ardeparin 50/kgx2 +elastic stockings (n=122)

vs.

Placebo+elastic stockings (n=124)

double blind

Sample size: 122/124

Primary endpoint:

FU duration: 14 days

major haemorrhage ∞ [NaN; ∞]

clinical PE NaN [NaN; NaN]

asymptomatic DVT ∞ [NaN; ∞]

wound hematoma 2.13 [0.61; 7.41]

symptomatic thromboembolism NaN [NaN; NaN]

transfusion 0.59 [0.35; 0.99]

death 0.39 [0.08; 1.95]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 1.01 [0.50; 2.07]

wound hematoma 1.33 [0.23; 7.74]

death 0.63 [0.18; 2.16]

total haemorrhage 0.51 [0.20; 1.34]

major haemorrhage 2.83 [0.30; 26.70]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 0.94 [0.06; 14.85]

wound hematoma 0.30 [0.06; 1.47]

symptomatic thromboembolism 0.00 [0.00; NaN]

transfusion 0.91 [0.71; 1.16]

asymptomatic DVT 0.30 [0.10; 0.88]

wound hematoma 1.50 [0.31; 7.19]

total haemorrhage 2.07 [0.53; 8.01]

major haemorrhage ∞ [NaN; ∞]

clinical PE ∞ [NaN; ∞]

asymptomatic DVT 0.83 [0.34; 2.00]

wound hematoma 2.00 [0.15; 26.19]

clinical PE 3.00 [0.26; 34.58]

asymptomatic DVT 1.50 [0.54; 4.14]

wound hematoma 0.74 [0.23; 2.33]

transfusion 1.31 [0.95; 1.81]

death 0.52 [0.05; 5.59]

major haemorrhage NaN [NaN; NaN]

clinical PE 1.00 [0.05; 18.57]

asymptomatic DVT 0.88 [0.31; 2.50]

wound hematoma ∞ [NaN; ∞]

major haemorrhage 0.97 [0.44; 2.15]

clinical PE ∞ [NaN; ∞]

Certoparin (dose 1 and dose 2) b.i.d. (n=84)

vs.

UFH 10 000 units (n=42)

Blind

Sample size: 84/42

Primary endpoint:

FU duration: 1 month

Certoparin 3000 + DHE (n=137)

vs.

UFH 10 000 units +DHE (n=132)

Blind

Sample size: 137/132

Primary endpoint:

FU duration: 7 days

Certoparin 3000 + DHE (n=103)

vs.

UFH 10 000 units (n=97)

Blind

Sample size: 103/97

Primary endpoint:

FU duration: 10 days

Certoparin 2500 + DHE (n=98)

vs.

UFH 10 000 units+DHE (n=103)

Open

Sample size: 98/103

Primary endpoint:

FU duration: 7 days

Certoparin 3000 + DHE (n=88)

vs.

UFH 10 000 units+DHE (n=91)

Blind

Sample size: 88/91

Primary endpoint:

FU duration:

Certoparin 3000 (n=205)

vs.

UFH 15 000 units (n=205)

Blind

Sample size: 205/205

Primary endpoint:

FU duration: 1 month

Certoparin 3000 + DHE (n=99)

vs.

UFH 5 000 units+DHE (n=102)

Blind

Sample size: 99/102

Primary endpoint:

FU duration: 10 days

Certoparin 3000 + DHE (n=464)

vs.

UFH 10 000 units (n=452)

NA

Sample size: 464/452

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=51)

vs.

UFH 15 000 units (n=53)

Blind

Sample size: 51/53

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units + DHE (n=47)

vs.

UFH 10 000 units + DHE (n=51)

Open

Sample size: 47/51

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=336)

vs.

UFH 15 000 units (n=337)

Blind

Sample size: 336/337

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=298)

vs.

UFH 10 000 units (n=296)

Blind

Sample size: 298/296

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=11542)

vs.

UFH 15 000 units (n=11536)

Blind

Sample size: 11542/11536

Primary endpoint:

FU duration:

major haemorrhage 0.67 [0.11; 3.93]

clinical PE NaN [NaN; NaN]

asymptomatic DVT 0.33 [0.07; 1.63]

wound hematoma 0.70 [0.24; 2.10]

Certoparin 3000 (n=150)

vs.

UFH 15 000 units (n=150)

Blind

Sample size: 150/150

Primary endpoint:

FU duration: 10 days

Certoparin 3000 anti Xa units (n=179)

vs.

UFH 15 000 units (n=179)

Blind

Sample size: 179/179

Primary endpoint:

FU duration:

Sandoz +0.5mg DHE (n=80)

vs.

Unfractionated heparin (n=80)

Sample size: 80/80

Primary endpoint:

FU duration:

certoparin 3000+0.5mg DHE, x1 (n=118)

vs.

Placebo (n=122)

double blind

Sample size: 118/122

Primary endpoint:

FU duration: 6 days

certoparin 3000+0.5mg DHE x1 (n=68)

vs.

placebo (n=71)

double blind

Sample size: 68/71

Primary endpoint:

FU duration: 6 days

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

Asymptomatic Deep vein thrombosis 0.26 [0.09; 0.77]

all cause death 0.00 [0.00; NaN]

total bleeding 2.33 [0.76; 7.17]

major Bleeding 0.93 [0.24; 3.62]

Pulmonary embolism 0.00 [0.00; NaN]

wound hematoma ∞ [NaN; ∞]

Dalteparin 2500 anti-Xa units (n=102)

vs.

Placebo (n=95)

Blind

Sample size: 102/95

Primary endpoint:

FU duration:

total haemorrhage 2.52 [1.24; 5.13]

transfusion 1.38 [1.03; 1.84]

major haemorrhage 3.36 [0.94; 12.06]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 1.46 [0.64; 3.34]

wound hematoma 1.86 [0.50; 6.84]

death NaN [NaN; NaN]

total haemorrhage 0.54 [0.05; 5.59]

major haemorrhage 1.08 [0.07; 16.36]

clinical PE NaN [NaN; NaN]

asymptomatic DVT ∞ [NaN; ∞]

wound hematoma 0.00 [0.00; NaN]

total haemorrhage 4.78 [1.20; 19.06]

death NaN [NaN; NaN]

major haemorrhage 2.61 [0.59; 11.50]

wound hematoma 3.50 [0.57; 21.67]

transfusion 4.35 [0.55; 34.17]

death NaN [NaN; NaN]

total haemorrhage 1.00 [0.46; 2.16]

major haemorrhage ∞ [NaN; ∞]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 1.94 [0.18; 20.93]

wound hematoma 1.50 [0.20; 11.24]

transfusion 0.80 [0.22; 2.86]

total haemorrhage 0.62 [0.29; 1.32]

major haemorrhage 2.00 [0.19; 21.19]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT NaN [NaN; NaN]

symptomatic thromboembolism 0.20 [0.02; 1.64]

total haemorrhage 1.97 [1.07; 3.61]

death 0.98 [0.41; 2.34]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 0.67 [0.42; 1.07]

wound hematoma 2.50 [0.77; 8.13]

transfusion 1.02 [0.89; 1.17]

death 0.65 [0.11; 3.84]

total haemorrhage 0.97 [0.25; 3.84]

major haemorrhage 0.00 [0.00; NaN]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 0.84 [0.29; 2.44]

wound hematoma 1.33 [0.23; 7.74]

transfusion 1.34 [0.55; 3.26]

transfusion 0.22 [0.05; 0.99]

death 1.48 [0.43; 5.10]

total haemorrhage 0.98 [0.25; 3.85]

major haemorrhage 0.66 [0.11; 3.86]

clinical PE 1.00 [0.05; 18.57]

asymptomatic DVT 1.03 [0.31; 3.45]

wound hematoma 1.00 [0.05; 18.57]

Dalteparin 5000 (n=215)

vs.

UFH 10 000 units (n=217)

Blind

Sample size: 215/217

Primary endpoint:

FU duration: 1 month

Dalteparin 5000 (n=25)

vs.

UFH 10 000 units (n=27)

Blind

Sample size: 25/27

Primary endpoint:

FU duration: 1 month

Dalteparin 7500 (n=23)

vs.

UFH 10 000 units (n=20)

Blind

Sample size: 23/20

Primary endpoint:

FU duration: 30 days

Dalteparin 2500 (n=75)

vs.

UFH 10 000 units (n=75)

Blind

Sample size: 75/75

Primary endpoint:

FU duration: 30 days

Dalteparin 5000 (n=40)

vs.

UFH 15 000 units (n=40)

Open

Sample size: 40/40

Primary endpoint:

FU duration: 1-2 months

Dalteparin 5000 (n=505)

vs.

UFH 10 000 units (n=497)

Blind

Sample size: 505/497

Primary endpoint:

FU duration: 1 month

Dalteparin 2500 (n=195)

vs.

UFH 10 000 units (n=190)

Blind

Sample size: 195/190

Primary endpoint:

FU duration: 1 month

Dalteparin 2500 (n=126)

vs.

UFH 10 000 units (n=124)

Blind

Sample size: 126/124

Primary endpoint:

FU duration: > 7 days

Dalteparin 2500 anti Xa units (n=1894)

vs.

UFH 10 000 units (n=1915)

Blind

Sample size: 1894/1915

Primary endpoint:

FU duration:

clinical PE NaN [NaN; NaN]

asymptomatic DVT 1.67 [0.46; 6.06]

symptomatic thromboembolism NaN [NaN; NaN]

Dalteparin 2500 (n=20)

vs.

UFH 10 000 units (n=20)

Blind

Sample size: 20/20

Primary endpoint:

FU duration:

total haemorrhage 1.16 [0.91; 1.49]

major haemorrhage 1.05 [0.07; 16.53]

clinical PE NaN [NaN; NaN]

asymptomatic DVT NaN [NaN; NaN]

wound hematoma 1.73 [0.56; 5.32]

symptomatic thromboembolism NaN [NaN; NaN]

Dalteparin 5000 (n=105)

vs.

UFH 10 000 units (n=110)

Blind

Sample size: 105/110

Primary endpoint:

FU duration:

Dalteparin 2500 anti Xa units (n=77)

vs.

UFH 10 000 units (n=75)

Blind

Sample size: 77/75

Primary endpoint:

FU duration:

dalteparin 5000 x1 (n=30)

vs.

Placebo (n=38)

double blind

Sample size: 30/38

Primary endpoint:

FU duration: 9 days

dalteparin 5000x1 (n=58)

vs.

Placebo (n=54)

double blind

Sample size: 58/54

Primary endpoint:

FU duration: 9 days

dalteparin (n=50)

vs.

Dextran (n=50)

Sample size: 50/50

Primary endpoint:

FU duration:

dalteparin (n=48)

vs.

Dextran (n=52)

Sample size: 48/52

Primary endpoint:

FU duration:

dalteparin (n=120)

vs.

Dextran (n=123)

Sample size: 120/123

Primary endpoint:

FU duration:

dalteparin (n=65)

vs.

Unfractionated heparin (n=65)

Sample size: 65/65

Primary endpoint:

FU duration:

dalteparin (n=48)

vs.

Unfractionated heparin (n=47)

Sample size: 48/47

Primary endpoint:

FU duration:

dalteparin (n=40)

vs.

Unfractionated heparin (n=40)

Sample size: 40/40

Primary endpoint:

FU duration:

dalteparin (n=82)

vs.

Unfractionated heparin (n=40)

Sample size: 82/40

Primary endpoint:

FU duration:

dalteparin (n=67)

vs.

Unfractionated heparin (n=69)

Sample size: 67/69

Primary endpoint:

FU duration:

dalteparin (n=46)

vs.

Unfractionated heparin (n=44)

Sample size: 46/44

Primary endpoint:

FU duration:

DVT 0.49 [0.32; 0.75]

Asymptomatic deep vein thrombosis during follow-up. 0.51 [0.32; 0.80]

All-cause death during follow-up 1.02 [0.67; 1.55]

Major bleeding during follow-up ∞ [NaN; ∞]

Symptomatic pulmonary embolism during follow-up 0.83 [0.25; 2.72]

fatal PE 0.00 [0.00; NaN]

PE 0.83 [0.25; 2.73]

Symptomatic deep vein thrombosis during follow-up 0.45 [0.16; 1.30]

Dalteparin 5000E once daily, 1' days (n=1856)

vs.

placebo (n=1850)

double blind

Parallel groups

Sample size: 1856/1850

Primary endpoint:

FU duration: 21 days

PE 0.56 [0.34; 0.92]

Venous thromboembolism or death 0.90 [0.82; 0.99]

All-cause death during follow-up 0.90 [0.80; 1.01]

Major bleeding during follow-up 0.98 [0.75; 1.28]

DVT 0.86 [0.69; 1.07]

proximal deep-vein thrombosis 0.88 [0.67; 1.15]

subcutaneous dalteparin 5000 IU once daily (n=1873)

vs.

unfractionated heparin 5000 IU twice daily (n=1873)

double-blind

Parallel groups

Sample size: 1873/1873

Primary endpoint: proximal leg deep-vein thrombosis

FU duration:

asymptomatic DVT 1.03 [0.07; 16.26]

wound hematoma 1.50 [0.20; 11.24]

Dalteparin 5000 (n=95)

vs.

UFH 10 000 units+DHE (n=98)

NA

Sample size: 95/98

Primary endpoint:

FU duration:

total bleeding 3.78 [1.04; 13.70]

wound hematoma ∞ [NaN; ∞]

symptomatic thromboembolism event 0.00 [0.00; NaN]

transfusin 1.43 [0.85; 2.43]

thromboembolic events (symptomatic or asymptomatic) 0.51 [0.33; 0.80]

proxymal DVT 0.39 [0.17; 0.90]

thromboembolic events (symptomatic or asymptomatic) 0.65 [0.31; 1.34]

Enoxaparin 4000 anti-Xa units (n=134)

vs.

No treatment (n=169)

Open

Sample size: 134/169

Primary endpoint:

FU duration:

Enoxaparin, 40 mg/d subcutaneously within 24 hours postoperatively plus compression stockings for >=7 days (n=153)

vs.

compression stockings + placebo (n=154)

Sample size: 153/154

Primary endpoint:

FU duration: 30 days

Enoxaparin, 20 mg/d subcutaneously 18-24 hours postoperatively for 10 days (n=67)

vs.

placebo (n=63)

Sample size: 67/63

Primary endpoint:

FU duration: NA

Enoxaparin 4000 anti Xa units (n=674)

vs.

UFH 15 000 units (n=675)

Blind

Sample size: 674/675

Primary endpoint:

FU duration:

Bemiparin 2500 anti Xa units (n=84)

vs.

UFH 10 000 units (n=82)

Blind

Sample size: 84/82

Primary endpoint:

FU duration:

Enoxaparin 4000 anti Xa units (n=555)

vs.

UFH 15 000 units (n=560)

Blind

Sample size: 555/560

Primary endpoint:

FU duration:

death ∞ [NaN; ∞]

total haemorrhage 0.50 [0.15; 1.62]

major haemorrhage 0.99 [0.06; 15.76]

clinical PE NaN [NaN; NaN]

asymptomatic DVT 0.50 [0.19; 1.29]

wound hematoma 0.25 [0.02; 2.70]

symptomatic thromboembolism ∞ [NaN; ∞]

transfusion 1.21 [0.93; 1.57]

death ∞ [NaN; ∞]

total haemorrhage 0.68 [0.34; 1.37]

major haemorrhage ∞ [NaN; ∞]

clinical PE NaN [NaN; NaN]

asymptomatic DVT 1.04 [0.21; 5.03]

wound hematoma 0.67 [0.20; 2.26]

symptomatic thromboembolism 0.00 [0.00; NaN]

transfusion 0.97 [0.73; 1.29]

death ∞ [NaN; ∞]

total haemorrhage 0.92 [0.51; 1.67]

major haemorrhage 0.92 [0.06; 14.56]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 0.78 [0.21; 2.83]

wound hematoma 0.94 [0.29; 3.00]

symptomatic thromboembolism 0.46 [0.04; 5.01]

transfusion 1.05 [0.84; 1.31]

Enoxaparin 2000 (n=168)

vs.

UFH 15 000 units (n=167)

Open

Sample size: 168/167

Primary endpoint:

FU duration: 7 days

Enoxaparin 4000 (n=127)

vs.

UFH 15 000 units (n=123)

Open

Sample size: 127/123

Primary endpoint:

FU duration: 7 days

Enoxaparin 6000 (n=160)

vs.

UFH 15 000 units (n=147)

Open

Sample size: 160/147

Primary endpoint:

FU duration: 7 days

Enoxaparin 2000 anti Xa units (n=561)

vs.

UFH 10 000 units (n=561)

Open

Sample size: 561/561

Primary endpoint:

FU duration:

Enoxaparin 2000 anti Xa units (n=737)

vs.

UFH 15 000 units (n=734)

Blind

Sample size: 737/734

Primary endpoint:

FU duration:

Enoxaparin 2000 anti Xa units (n=37)

vs.

UFH 10 000 units (n=31)

Blind

Sample size: 37/31

Primary endpoint:

FU duration:

Enoxaparin 3000 x2 (n=50)

vs.

Placebo (n=50)

double blind

Sample size: 50/50

Primary endpoint:

FU duration: 14 days or discharge

enoxaparin 4000x1+elastic stockings (n=85)

vs.

Placebo+elastic stockings (n=85)

double blind

Sample size: 85/85

Primary endpoint:

FU duration: 8-12 days

enoxaparin 4000x1 (n=13)

vs.

Placebo (n=14)

double blind

Sample size: 13/14

Primary endpoint:

FU duration: discharge (8-12 days )

enoxaparin 4000x1 + elastic stockings (n=78)

vs.

no treatment + elastic stockings (n=78)

open

Sample size: 78/78

Primary endpoint:

FU duration: 8-10 days

Enoxaparin (n=120)

vs.

Dextran (n=126)

Sample size: 120/126

Primary endpoint:

FU duration:

Enoxaparin (n=124)

vs.

Unfractionated heparin (n=113)

Sample size: 124/113

Primary endpoint:

FU duration:

Enoxaparin (n=333)

vs.

Unfractionated heparin (n=332)

Sample size: 333/332

Primary endpoint:

FU duration:

Enoxaparin 3000 x2 (n=65)

vs.

Placebo (n=64)

double blind

Sample size: 65/64

Primary endpoint:

FU duration: 14 days

All-cause death during follow-up 1.00 [0.82; 1.22]

Major bleeding during follow-up 1.40 [0.67; 2.94]

subcutaneous enoxaparin 40 mg daily for 10±4 days (n=4171)

vs.

placebo (n=4136)

double-blind

Parallel groups

Sample size: 4171/4136

Primary endpoint: death from any cause

FU duration: 30 days

Asymptomatic deep vein thrombosis during follow-up. 0.39 [0.22; 0.67]

All-cause death during follow-up 0.74 [0.36; 1.54]

Major bleeding during follow-up 1.48 [0.42; 5.21]

Symptomatic pulmonary embolism during follow-up 0.00 [0.00; NaN]

DVT 0.72 [0.49; 1.05]

PE 0.17 [0.02; 1.52]

Symptomatic deep vein thrombosis during follow-up 0.49 [0.05; 5.43]

Major bleeding during follow-up 0.40 [0.08; 2.03]

Symptomatic pulmonary embolism during follow-up 0.33 [0.04; 3.17]

PE 0.33 [0.04; 3.17]

Symptomatic deep vein thrombosis during follow-up 0.63 [0.21; 1.86]

Enoxaparin 20 mg or 40 mg once daily, 6–14 days (n=291)

vs.

placebo (n=288)

3 arms: 40 mg of enoxaparin, 20 mg of enoxaparin, or placebo subcutaneously once daily for 6 to 14 days

double blind

Parallel groups

Sample size: 291/288

Primary endpoint:

FU duration: 6-14 days

Enoxaparin 40 mg once daily, until hospital discharge (n=140)

vs.

placebo (n=140)

double blind

Parallel groups

Sample size: 140/140

Primary endpoint:

FU duration: 90 days

All-cause death during follow-up 0.90 [0.33; 2.45]

DVT 0.94 [0.39; 2.26]

PE 3.13 [0.13; 75.88]

All-cause death during follow-up 0.64 [0.25; 1.64]

DVT 0.25 [0.03; 2.16]

PE 0.11 [0.01; 1.58]

All-cause death during follow-up 0.60 [0.27; 1.35]

DVT 0.77 [0.43; 1.38]

PE 0.89 [0.06; 13.64]

enoxaparin 20 mg once daily for 10 days (n=-9)

vs.

unfractionated heparin (UFH) 5000 IU twice daily (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 10 days

enoxaparin 40 mg (n=-9)

vs.

unfractionated heparin (Ca-heparin), 3 x 5,000 U) (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 7 days

enoxaparin 40 mg once daily for 10 +/2 days (n=-9)

vs.

UFH 5000 IU 3 times daily for 10 +/2 days (n=-9)

open

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 10 +/- 2 days

symptomatic thromboembolism event 0.29 [0.11; 0.80]

total bleeding 2.09 [1.80; 2.44]

major Bleeding 2.51 [1.91; 3.30]

wound hematoma 1.88 [1.55; 2.29]

transfusin 1.65 [1.34; 2.03]

all cause death 0.45 [0.19; 1.02]

Pulmonary embolism 0.25 [0.05; 1.18]

Nadroparin 2850 anti-Xa units (n=2247)

vs.

Placebo (n=2251)

Blind

Sample size: 2247/2251

Primary endpoint:

FU duration:

Fraxiparin (n=203)

vs.

Unfractionated heparin (n=206)

Sample size: 203/206

Primary endpoint:

FU duration:

All-cause death during follow-up 2.93 [0.31; 27.64]

DVT 0.70 [0.16; 3.05]

All-cause death during follow-up 2.46 [1.15; 5.27]

DVT 2.89 [0.30; 27.78]

PE 0.96 [0.19; 4.81]

1 x 1.500 aPTT units of a LMW heparin fraction (n=-9)

vs.

3 x 5.000 IU of an unfractionated heparin (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 10 days

1 daily subcutaneous administration of LMW heparin for 10 days (n=-9)

vs.

3 x 5,000 IU unfractionated (UF) heparin for 10 days (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 10 days

total bleeding 0.58 [0.17; 1.91]

total bleeding 0.00 [0.00; NaN]

wound hematoma 0.00 [0.00; NaN]

transfusin 1.15 [0.65; 2.04]

thromboembolic events (symptomatic or asymptomatic) 0.71 [0.48; 1.06]

proxymal DVT 0.60 [0.30; 1.18]

Nadroparin 2850 anti-Xa units (n=94)

vs.

Placebo (n=95)

Blind

Sample size: 94/95

Primary endpoint:

FU duration:

Nadroparin 2850 anti-Xa units (n=31)

vs.

No treatment (n=33)

Open

Sample size: 31/33

Primary endpoint:

FU duration:

Nadroparin, 7500 Institute Choay anti-Xa units per day subcutaneously 18-24 hours postoperatively plus compression for 10 days (n=241)

vs.

compression stockings + placebo (n=244)

Sample size: 241/244

Primary endpoint:

FU duration: 56 days

symptomatic thromboembolism 0.27 [0.07; 0.95]

death 0.89 [0.40; 2.01]

total haemorrhage 0.99 [0.82; 1.19]

clinical PE 0.20 [0.02; 2.07]

asymptomatic DVT 0.63 [0.39; 1.01]

wound hematoma 0.97 [0.37; 2.55]

transfusion 1.01 [0.82; 1.25]

Nadroparin 2850 (n=968)

vs.

UFH 15 000 units (n=941)

Open

Sample size: 968/941

Primary endpoint:

FU duration: 1 month

Nadroparin 2850 anti Xa units (n=241)

vs.

UFH 15 000 units (n=239)

Open

Sample size: 241/239

Primary endpoint:

FU duration:

asymptomatic DVT 0.36 [0.13; 0.99]

death 0.83 [0.26; 2.69]

clinical PE 0.00 [0.00; NaN]

wound hematoma 0.79 [0.23; 2.65]

symptomatic thromboembolism 0.00 [0.00; NaN]

transfusion 1.14 [0.85; 1.53]

Nadroparin 2850 (n=200)

vs.

UFH 10 000 units (n=200)

Blind

Sample size: 200/200

Primary endpoint:

FU duration: 10 days

Nadroparin 2850 anti Xa units (n=171)

vs.

UFH 10 000 units (n=173)

Open

Sample size: 171/173

Primary endpoint:

FU duration:

nadroparin 41/kgx1 days 1-3, 62/kg x1 days 4-11+elastic stockings (n=50)

vs.

no treatment (n=50)

open

Sample size: 50/50

Primary endpoint:

FU duration: 10 days

nadroparin 3075x1 preop, 6150x1 post op (n=72)

vs.

Placebo (n=78)

double blind

Sample size: 72/78

Primary endpoint:

FU duration: 10-12 days

All-cause death during follow-up 1.05 [0.41; 2.69]

Major bleeding during follow-up 2.09 [0.54; 8.16]

Symptomatic pulmonary embolism during follow-up NaN [NaN; NaN]

DVT 0.55 [0.30; 1.00]

Asymptomatic deep vein thrombosis during follow-up. 0.57 [0.30; 1.06]

Symptomatic deep vein thrombosis during follow-up NaN [NaN; NaN]

All-cause death during follow-up 0.98 [0.78; 1.24]

Major bleeding during follow-up 0.34 [0.04; 3.24]

Symptomatic pulmonary embolism during follow-up 0.59 [0.27; 1.29]

fatal PE 0.59 [0.27; 1.29]

PE 0.59 [0.27; 1.29]

All-cause death during follow-up 0.98 [0.78; 1.24]

Nadroparin 3800–5700E once daily, Until no longer mechanical ventilation, <=21 days (n=109)

vs.

placebo (n=114)

double blind

Parallel groups

Sample size: 109/114

Primary endpoint:

FU duration: <=21 days

nadroparin 7500E once daily, Until hospital discharge, <=21 days (n=1230)

vs.

placebo (n=1244)

double blind

Parallel groups

Sample size: 1230/1244

Primary endpoint:

FU duration: <=21 days

nadroparin 7500 u anti-Xa once daily (n=-9)

vs.

placebo (n=-9)

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: up to 21

clinical PE NaN [NaN; NaN]

asymptomatic DVT NaN [NaN; NaN]

wound hematoma 0.00 [0.00; NaN]

Nadroparin 2850 (n=46)

vs.

UFH 15 000 units (n=41)

Open

Sample size: 46/41

Primary endpoint:

FU duration:

Reviparin 1750 anti Xa units (n=672)

vs.

UFH 10 000 units (n=679)

Blind

Sample size: 672/679

Primary endpoint:

FU duration:

all cause death 0.00 [0.00; NaN]

total bleeding ∞ [NaN; ∞]

major Bleeding ∞ [NaN; ∞]

Pulmonary embolism 0.00 [0.00; NaN]

Asymptomatic Deep vein thrombosis 0.35 [0.10; 1.20]

wound hematoma NaN [NaN; NaN]

Tinzaparin 3500 anti-Xa units (n=39)

vs.

Placebo (n=41)

Blind

Parallel groups

Sample size: 39/41

Primary endpoint:

FU duration:

Tinzaparin 2500 and 3500 anti Xa units (n=861)

vs.

UFH 10 000 units (n=429)

Blind

Sample size: 861/429

Primary endpoint:

FU duration:

tinzaparin 50/kg x1 +elastic stockings (n=105)

vs.

Placebo+elastic stockings (n=105)

double blind

Sample size: 105/105

Primary endpoint:

FU duration: 8-10 days

thromboembolic events (symptomatic or asymptomatic) 0.18 [0.06; 0.56]

Unfractionated heparin, 5000 IU subcutaneously 3 times a day, starting 2 hours preoperatively for +7 days (n=50)

vs.

no treatment (n=50)

Sample size: 50/50

Primary endpoint:

FU duration: NA

VTE during active anticoagulant treatment 0.78 [0.19; 3.19]

LMWH, 115 IU/kg qd followed by Bemiparin 3,500 IU qd (n=221)

vs.

A: UFH, 30/40,000IU qd; B: LMWH, 115 IU/kg qd followed by Warfarin target INR 2-3 (n=103)

open

Sample size: 221/103

Primary endpoint: none defined

FU duration: 3 mo

VTE during active anticoagulant treatment 2.75 [0.56; 13.55]

VTE during active anticoagulant treatment 0.51 [0.33; 0.79]

UFH followed by Dalteparin 5,000 IU qd (n=50)

vs.

UFH followed by Warfarin target INR 2-3 (n=55)

open

Sample size: 50/55

Primary endpoint: recurrent venous thromboembolism

FU duration: 3 mo

LMWH, 200 IU/kg qd followed by Dalteparin 150 IU/kg qd (n=336)

vs.

LMWH, 200 IU/kg qd followed by Warfarin target INR 2-3 (n=336)

open

Sample size: 336/336

Primary endpoint: recurrent thrombosis

FU duration: 6 mo

all cause death NaN [NaN; NaN]

Recurrent thromboembolic event NaN [NaN; NaN]

Thrombus extension 0.00 [0.00; NaN]

Short term haemorrhage ∞ [NaN; ∞]

all cause death NaN [NaN; NaN]

Recurrent thromboembolic event ∞ [NaN; ∞]

Thrombus extension 0.47 [0.04; 4.85]

Short term haemorrhage NaN [NaN; NaN]

all cause death 1.83 [0.72; 4.64]

Recurrent thromboembolic event 0.67 [0.20; 2.24]

Thrombus extension 0.67 [0.12; 3.85]

Short term haemorrhage 0.00 [0.00; NaN]

all cause death 0.68 [0.12; 3.98]

Recurrent thromboembolic event 2.04 [0.52; 7.93]

Thrombus extension 0.73 [0.24; 2.22]

Short term haemorrhage NaN [NaN; NaN]

Dalteparin Intravenousv (ajusted) for >=5 Days, 120 U/kg BID (n=25)

vs.

unfractionated heparin intravenous APPTx1.7-3.5 (n=29)

Sample size: 25/29

Primary endpoint:

FU duration: 23 Months (mean)

Dalteparin Subcutaneous twice daily ajusted for 7 Days, 57-107 U/kg BID (n=29)

vs.

unfractionated heparin subcutaneous twice daily 16000-30000 U (n=27)

Sample size: 29/27

Primary endpoint:

FU duration: Hospital Stay

Dalteparin Subcutaneous twice daily ajusted for >= 5 Days, 120 U/kg BID (n=60)

vs.

unfractionated heparin intravenous APPTx2-4 (n=60)

Sample size: 60/60

Primary endpoint:

FU duration: Hospital stay

Dalteparin Subcutaneous once daily for >= 5 Days, 200 U/kg BID (n=101)

vs.

unfractionated heparin intravenous APPTx1.5-3 (n=103)

Sample size: 101/103

Primary endpoint:

FU duration: 6 Months

Improvement of thrombus size 1.07 [0.72; 1.59]

Haemorraghic events 0.00 [0.00; NaN]

Mortality 2.53 [0.27; 23.70]

Haemorraghic events ∞ [NaN; ∞]

once daily dalteparin 200 U (anti-FXa)/kg for at least 5 days (n=50)

vs.

twice daily dalteparin 100 U (anti-FXa)/kg for at least 5 days (n=51)

open

Parallel groups

Sample size: 50/51

Primary endpoint:

FU duration:

Fragmin administered 200 IU/kg once daily for at least 7 days (n=76)

vs.

Fragmin 100 IU/kg twice daily for at least 7 days (n=64)

NA

Parallel groups

Sample size: 76/64

Primary endpoint:

FU duration:

VTE during follow-up after active anticoagulant treatment 2.56 [0.83; 7.85]

VTE during active anticoagulant treatment 1.52 [0.44; 5.20]

VTE during active anticoagulant treatment 0.42 [0.19; 0.90]

VTE during follow-up after active anticoagulant treatment 1.25 [0.41; 3.82]

VTE during active anticoagulant treatment 2.00 [0.19; 21.36]

VTE during follow-up after active anticoagulant treatment ∞ [NaN; ∞]

VTE during active anticoagulant treatment 0.59 [0.09; 3.96]

VTE during active anticoagulant treatment 1.97 [1.06; 3.66]

UFH, APTT 1.3–1.9 followed by Enoxaparin 4,000 IU qd (n=93)

vs.

UFH, APTT 1.3–1.9 followed by Warfarin target INR 2-3.5 (n=94)

open

Sample size: 93/94

Primary endpoint: none defined

FU duration: 9 mo

LMWH, 4,000 IU bid followed by Enoxaparin 4,000 IU qd (n=93)

vs.

UFH followed by Warfarin target INR 2-3 (n=92)

open

Parallel groups

Sample size: 93/92

Primary endpoint: none defined

FU duration: 9 mo

UFH, APTT 1.5–2.0d followed by Enoxaparin 4,000 IU qd (n=50)

vs.

UFH, APTT 1.5–2.0d followed by Acenocoumarol target INR 2-3 (n=50)

open

Sample size: 50/50

Primary endpoint: none defined

FU duration: 6-9 mo

LMWH, 1.5 mg/kg qd followed by Enoxaparin 1.5 mg/Kg qd (n=71)

vs.

LMWH, 1.5 mg/kg qd followed by Warfarin target INR 2-3 (n=58)

open

Sample size: 71/58

Primary endpoint: major bleeding or recurrent venous thromboembolism

FU duration: 3 mo

LMWH: 1a, 1 mg/kg q12h; 1b, 1 mg/kg qd12h followed by Enoxaparin 1a: 1 mg/kg qd; 1b: 1.5 mg/kg qd (n=51)

vs.

LMWH, 1 mg/kg q12h followed by Warfarin target INR 2-3 (n=30)

open

Sample size: 51/30

Primary endpoint:

FU duration: 6 mo

long-term anticoagulant treatment with enoxaparin during at least 3 months (n=85)

vs.

long-term anticoagulant treatment with coumarin during at least 3 months (n=80)

open, blind assessment

Parallel groups

Sample size: 85/80

Primary endpoint: incidence of post-thrombotic syndrome

FU duration: 1y, 5y

all cause death 1.50 [0.26; 8.69]

Recurrent thromboembolic event 0.00 [0.00; NaN]

Thrombus extension 0.14 [0.02; 1.13]

Short term haemorrhage NaN [NaN; NaN]

Enoxaparin Subcutaneous twice daily for 0 Days, 100 U/kg BID (n=67)

vs.

unfractionated heparin intravenous APPTx1.5-2.5 (n=67)

Sample size: 67/67

Primary endpoint:

FU duration: 3 Months

Mortality 1.65 [0.65; 4.19]

Haemorraghic events 1.31 [0.35; 4.83]

Recurrent thromboembolic events 1.51 [0.66; 3.49]

enoxaparin 1.5 mg/kg body weight once daily (n=298)

vs.

S.c. enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily (n=312)

double blind

Parallel groups

Sample size: 298/312

Primary endpoint:

FU duration:

Mortality 1.19 [0.50; 2.83]

Haemorraghic events 1.15 [0.77; 1.70]

Recurrent thromboembolic events 1.05 [0.49; 2.27]

Initial therapy with enoxaparin 1.5 mg/kg body weight once daily (n=298)

vs.

Initial therapy with dose-adjusted intravenous unfractionated heparin (n=290)

partialy blinded

Parallel groups

Sample size: 298/290

Primary endpoint: occurrence of symptomatic recurrent venous thromboembolism

FU duration: 3 months

Improvement of thrombus size 2.00 [0.68; 5.85]

Mortality NaN [NaN; NaN]

Haemorraghic events NaN [NaN; NaN]

Recurrent thromboembolic events NaN [NaN; NaN]

Once daily logiparin 150 XaI U/kgp, imag (n=10)

vs.

twice daily logiparin 75 XaI U/kg (n=10)

single blind

Parallel groups

Sample size: 10/10

Primary endpoint:

FU duration:

VTE during follow-up after active anticoagulant treatment 2.53 [0.50; 12.71]

VTE during active anticoagulant treatment 0.43 [0.11; 1.61]

VTE during follow-up after active anticoagulant treatment 0.50 [0.09; 2.65]

VTE during active anticoagulant treatment 2.85 [0.80; 10.14]

LMWH, 85 UI/kg bid followed by Nadroparin 85 IU/kg qd (n=101)

vs.

LMWH, 85 UI/kg bid followed by Acenocoumarol target INR 2-3 (n=101)

open

Sample size: 101/101

Primary endpoint: none defined

FU duration: 9 mo

LMWH, 1,025 IU/10 kg bid followed by Nadroparin 1,025 IU/10 kg bid (n=81)

vs.

LMWH, 1,025 IU/10 kg bid followed by Acenocoumarol target INR 2-3 (n=77)

open

Sample size: 81/77

Primary endpoint: none defined

FU duration: 6-9 mo

all cause death 1.89 [0.18; 20.31]

Recurrent thromboembolic event 2.83 [0.30; 26.52]

Thrombus extension 0.47 [0.09; 2.49]

Short term haemorrhage 1.89 [0.36; 9.95]

Thrombus extension 0.36 [0.13; 0.95]

all cause death 0.50 [0.20; 1.27]

Recurrent thromboembolic event 0.50 [0.20; 1.27]

Short term haemorrhage 0.33 [0.04; 3.14]

all cause death 0.00 [0.00; NaN]

Recurrent thromboembolic event 0.00 [0.00; NaN]

Thrombus extension 0.84 [0.39; 1.83]

Short term haemorrhage 0.00 [0.00; NaN]

Nadroparin Subcutaneous twice daily for 10 Days, 90 U/kg BID (n=70)

vs.

unfractionated heparin intravenous APPTx1.5-2 (n=66)

Sample size: 70/66

Primary endpoint:

FU duration: 12 Weeks

Nadroparin Subcutaneous twice daily for >=0 Days, 90 U/kg BID (n=85)

vs.

unfractionated heparin intravenous APPTx1.5-2 (n=85)

Sample size: 85/85

Primary endpoint:

FU duration: 6 Months

Nadroparin Subcutaneous twice daily for 10 Days, 92 U/kg BID (n=74)

vs.

unfractionated heparin subcutaneous twice daily APPTx1.5-2.5 (n=75)

Sample size: 74/75

Primary endpoint:

FU duration: 3 Months

Mortality 0.73 [0.32; 1.69]

Haemorraghic events 0.62 [0.29; 1.34]

Recurrent thromboembolic events 0.57 [0.30; 1.11]

Once daily nadroparin 20,500 (AXa IU/ml)continued for at least 5 days (n=316)

vs.

twice daily nadroparin 10,250 (AXa IU/ml)continued for at least 5 days (n=335)

double blind

Parallel groups

Sample size: 316/335

Primary endpoint:

FU duration:

VTE during follow-up after active anticoagulant treatment 1.00 [0.50; 2.01]

VTE during active anticoagulant treatment 0.76 [0.40; 1.43]

DVT (recurrent) 0.21 [0.05; 0.92]

bleeding 0.34 [0.04; 3.24]

VTE at the end of trial 0.47 [0.19; 1.20]

VTE during follow-up after active anticoagulant treatment 0.17 [0.02; 1.40]

VTE during active anticoagulant treatment 0.73 [0.24; 2.24]

PE 1.37 [0.31; 5.98]

LMWH, 175 IU/kg qd followed by Tinzaparin 175 IU/kg qd (n=369)

vs.

UFH 5 d, followed by UFH therapeutic APTT followed by Warfarin target INR 2-3 (n=368)

open

Sample size: 369/368

Primary endpoint:

FU duration: 9 mo

tinzaparin SC 175 IU anti-Xa per kg once daily for 6 months (n=119)

vs.

acenocoumarol for target INR 2-3 for 6 months after initial LMWH (until INR 2-3) (n=122)

open

Parallel groups

Sample size: 119/122

Primary endpoint: symptomatic recurrent venous thromboembolism

FU duration: 12 months

Short term haemorrhage 0.09 [0.01; 0.72]

all cause death 0.49 [0.24; 1.02]

Recurrent thromboembolic event 0.41 [0.16; 1.04]

Tinzaparin Subcutaneous once daily for >= Days, 175 U/kg BID (n=213)

vs.

unfractionated heparin intravenous APPTx2-3 (n=219)

Sample size: 213/219

Primary endpoint:

FU duration: 3 Months